Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.

Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.

Show other versions (1)

<h4>Background and aims</h4>Metabolic dysfunction associated steatotic liver disease (MASLD) increases the risk of incident chronic kidney disease (CKD). However, the relative risk of CKD associated with increasing hepatic fibrosis, and consequent mortality risk, remains underexplored in...

Full description

Bibliographic Details
Main Authors: Marc Gurun, Paul Brennan, Sava Handjiev, Aseil Khatib, Damien Leith, John F Dillon, Christopher J Byrne
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0299507

Internet

https://doi.org/10.1371/journal.pone.0299507

Similar Items